Senior Management

Professor Greg Hannon,

Prof Hannon joined the Institute in 2014 as a Senior Group Leader, after spending more than 20 years at Cold Spring Harbor Laboratory in New York. He became Director on 1 February 2018, taking over from Professor Simon Tavaré. Read more.

Karen Woodey,
Director of Operations

Karen Woodey joined as Director of Operations on 1 August 2019. Karen is responsible for all aspects of the operation of the Institute including long-term strategic planning and providing support and infrastructure to the Director.

Executive committee

Prof Sir Steve Jackson,
Associate Director of Enterprise and Partnerships

Prof Sir Steve Jackson is a Senior Group Leader at the CRUK CI and the University of Cambridge Frederick James Quick Professor of Biology. He has founded three biotech companies : KuDOS Pharmaceuticals, Mission Therapeutics, and Adrestia Therapeutics.

Dr Raza Ali, Cancer Research UK Cambridge Institute

Dr Raza Ali,
Associate Director of Clinical Research

Dr Raza Ali joined the Institute as a Group Leader in 2020. His research models how the tumour-immune interaction changes over time in breast cancer.

Dr Maike de la Roche,
Associate Director of Research Culture and Innovation

Dr Maike de la Roche joined the Institute in 2016 as a Sir Henry Dale Fellow and Group Leader. Her work focuses on Hedgehog signalling in the immune system.

Prof Jason Carroll,
Associate Director of Research Culture and Innovation

Prof Jason Carroll is a Senior Group Leader at the Institute and Professor of Molecular Oncology within the University. His research focuses on nuclear receptor transcription.

Florian Markowetz Cambridge

Prof Florian Markowetz,
Associate Director of Artificial Intelligence

Prof Florian Markowetz is a Senior Group Leader at the Institute and Professor of Computational Oncology within the University. His research focuses on developing technologies for the clinic.

Richard Gilbertson standing outside of the Cancer Research UK Cambridge Institute

Prof Richard Gilbertson,
Director of the CRUK CC

Prof Richard Gilbertson is a senior Group Leader at the Institute and the Director of the CRUK Major Centre in Cambridge. He also serves as the Joint Delivery Board co-chair and research lead for the Cambridge Cancer Research Hospital.

Scientific Advisory Board

The Institute is guided and supported by an international Scientific Advisory Board.

The Board visits the Institute annually and is shared with the CRUK Cambridge Centre, to ensure the two are working in alignment.

Prof Douglas Fearon,
Cold Spring Harbor Laboratory

The Fearon laboratory studies the interaction between cancer and the immune system. Read more.

Prof Elaine Fuchs,
The Rockefeller University

Fuchs is renowned for her research in skin biology, its stem cells and associated genetic disorders, particularly cancers. Read more.

Prof Ed Harlow
Harvard Medical School

Ed Harlow and his laboratory study the mechanisms that underlie the early stages of cancer development. Read more.

Prof Daphne Haas-Kogan,
Dana-Farber Cancer Institute

The Haas-Kogan laboratory characterises aberrant signaling pathways in brain tumors and pediatric cancers.

Prof Peter Jones,
Van Andel Research Institute

Jones’ laboratory discovered the effects of 5-azacytidine on cytosine methylation and first established the link between DNA methylation, gene expression and differentiation. Read more.

Dr Scott Lowe,
Memorial Sloan Kettering Cancer Centre

Lowe’s laboratory applies mouse models, functional genomics and cancer genomics in a coordinated effort to identify cancer drivers and dependencies. Read more.

Dr John Marioni,
Genentech Research and Early Development

Marioni’s research uses computational models and statistical approaches to integrate and analyse omics cell data. Read more.

Ann Russell,
Patient Advocate

Russell has been a patient advocate since 2010. She is a founding member of the Cancer Patient Advisory Group at Cambridge University Hospital, involved in a wide range of patient fora and has taken part in various cancer trials and studies. Read more.

Prof Karen Vousden,
Francis Crick Institute

Vousden’s research has contributed to our understanding of how the tumour suppressor protein p53 is regulated and functions to control cancer progression. Read more.